Cole-Parmer Introduces Digi-Sense Precision Measurement Instruments - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cole-Parmer Introduces Digi-Sense Precision Measurement Instruments


The Digi-Sense brand offers new technologies that deliver accurate readings while withstanding rigorous use. The new line includes a range of instruments from environmental-testing meters to performance-monitoring equipment, and many of the items are precalibrated to save time, cost, and effort. The product line currently includes 25 models of thermometers, infrared devices, humidity meters, anemometers, light meters, and manometers. Additional products that fill other measurement needs will soon be available. Digi-Sense also features a comprehensive line of temperature probes with customization available for unique applications.

Source: Cole-Parmer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here